[1] Beninger P. Pharmacovigilance: An overview. Clin Ther. 2018;40(12):1991–2004.

[2] Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: Prospective analysis of 18 820 patients. BMJ. 2004;329(7456):15–19.

[3] Wang X, Hripcsak G, Markatou M, Friedman C. Active computerized pharmacovigilance using natural language processing, statistics, and electronic health records: A feasibility study. J Am Med Inform Assoc. 2009;16(3):328–337.

[4] Elkhawad AO. The role of Pharmacovigilance Center in Sudan in reporting adverse drug reactions. Pharmacoinformatics and drug discovery technologies: Theories and applications. IGI Global Scientific Publishing; 2012. pp. 344–354.

[5] Nikfarjam A, Sarker A, O’Connor K, Ginn R, Gonzalez G. Pharmacovigilance from social media: Mining adverse drug reaction mentions using sequence labeling with word embedding cluster features. J Am Med Inform Assoc. 2015;22(3):671–681.

[6] Guo HL, Hassan HM, Zhang Y, Dong SZ, Ding PP, Wang T, et al. Pyrazinamide induced rat cholestatic liver injury through inhibition of FXR regulatory effect on bile acid synthesis and transport. Toxicol Sci. 2016;152(2):417–428.

[7] Price J. Pharmacovigilance in crisis: Drug safety at a crossroads. Clin Ther. 2018;40(5):790–797.

[8] Shaw D, Graeme L, Pierre D, Elizabeth W, Kelvin C. Pharmacovigilance of herbal medicine. J Ethnopharmacol. 2012;140(3):513–518.

[9] Zhang L, Yan J, Liu X, Ye Z, Yang X, Meyboom R, et al. Pharmacovigilance practice and risk control of Traditional Chinese Medicine drugs in China: Current status and future perspective. J Ethnopharmacol. 2012;140(3):519–525.

[10] Musa TH, Akintunde TY, Gatasi G, Ghimire U, Kawuki J, Musa HH. A bibliometric analysis of the 100 topcited articles on global malnutrition indexed in Web of Science. J Public Health Emerg. 2021;5:36.

[11] Gatasi G, Musa TH, Odjidja EN. Bibliometric analysis of the top 100 cited articles on HIV/AIDS. Ann Infect. 2021;5:6.

[12] Kawuki J, Musa TH, Papabathini SS, Ghimire U, Obore N, Yu X. The 100 top-cited studies on Ebola: A bibliometric analysis. Electron J Gen Med. 2021;18(2):em276.

[13] Musa TH, Li W, Kawuki J, Wei P. The 100 top-cited articles on scrub typhus: A bibliometric analysis. Osong Public Health Res Perspect. 2021;12(2):126– 135.

[14] Samanci NS, Celik E. The top 100 cited articles in lung cancer - A bibliometric analysis. Contemp Oncol. 2020;24(1):17–28.

[15] Akintunde TY, Musa TH, Musa HH, Chen S, Ibrahim E, Muhideen S, et al. Mapping the global research output on Ebola vaccine from research indexed in web of science and scopus: a comprehensive bibliometric analysis. Hum Vaccin Immunother. 2021;17(11):4246–4258.

[16] Musa TH, Akintunde TY, Musa IH, Mohammed LA, Tassang AE, Musa HH. Rift valley fever: Thematic analysis of documents indexed in the Web of Science Core Collection database. Ann Infect. 2022;6:1.

[17] Zhang Y, Shaojun C, Akintunde TY, Okagbue EF, Isangha SO, Musa TH. Life course and mental health: A thematic and systematic review. Front Psychol. 2024;15:1329079.

[18] Akintunde TY, Chen S, Musa TH, Amoo FO, Adedeji A, Ibrahim E, et al. Tracking the progress in COVID- 19 and vaccine safety research - A comprehensive bibliometric analysis of publications indexed in Scopus database. Hum Vaccin Immunother. 2021;17(11):3887–3897.

[19] Ahmad T, Murad MA, Nasir S, Musa TH, Baig M, Hui J. Trends in hepatitis A research indexed in the Web of Science: A bibliometric analysis over the period from 1985 to 2019. Hum Vaccin Immunother. 2021;17(9):3221–3229.

[20] Musa IH, Afolabi LO, Zamit I, Musa TH, Musa HH, Tassang A, et al. Artificial intelligence and machine learning in cancer research: A systematic and thematic analysis of the top 100 cited articles indexed in Scopus database. Cancer Control. 2022;29:10732748221095946.

[21] Akintunde TY, Musa TH, Musa HH, Musa IH, Chen S, Ibrahim E, et al. Bibliometric analysis of global scientific literature on effects of COVID-19 pandemic on mental health. Asian J Psychiatr. 2021;63:102753.

[22] Wang L, Feng W, Duan J, Liang J. Pharmacovigilance bibliometrics: Visualizing thematic development in the category of pharmacology and pharmacy in Web of Science. Front Pharmacol. 2021;12:731757.

[23] Zhao Y, Wang T, Li G, Sun S. Pharmacovigilance in China: Development and challenges. Int J Clin Pharm. 2018;40(4):823–831.

[24] Sa R, Xu Y, Pan X, Wang Y, Lin Z, Zhang X, et al. A bibliometric analysis of research progress on pharmacovigilance and cancer from 2002 to 2021. Front Oncol. 2023;13:1078254.

[25] Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al.; PRISMA-P Group. Preferred reporting items for systematic review and metaanalysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.

[26] Van Eck N, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics. 2010;84(2):523–538.

[27] Aria M, Cuccurullo C. Bibliometrix: An R-tool for comprehensive science mapping analysis. J Informetrics. 2017;11(4):959–975.

[28] Sadatmoosavi A, Tajedini O, Esmaeili O, Abolhasani Zadeh F, Khazaneha M. Emerging trends and thematic evolution of breast cancer: Knowledge mapping and co-word analysis. JMIR Cancer. 2021;7(4):e26691.

[29] Della Vittoria Scarpati G, Calura E, Di Marino M, Romualdi C, Beltrame L, Malapelle U, et al. Analysis of differential miRNA expression in primary tumor and stroma of colorectal cancer patients. BioMed Res Int. 2014;2014(1):840921.

[30] Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–245.

[31] Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. JAMA. 1998;279(15):1200–1205.

[32] Edwards IR, Aronson JK. Adverse drug reactions: Definitions, diagnosis, and management. Lancet. 2000;356(9237):1255–1259.

[33] Hazell L, Shakir SA. Under-reporting of adverse drug reactions: A systematic review. Drug Saf. 2006;29(5):385–396.

[34] Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10(6):483–486.

[35] Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998;54(4):315–321.

[36] van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11(1):3–10.

[37] Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: An observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19(12):1579–1589.

[38] Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 1999;131(2):81–87.